In our earlier work, we showed that a normalized ratio of CSF CXCL13 to serum CXCL13, ICXCL13, is an excellent biomarker for the prediction of future MS inflammatory activity (attacks and new MRI lesions) in the two years following the diagnostic lumbar puncture (LP) [31]. This evidence concerns the gene CXCL13 and myeloid sarcoma.